Accelerate Diagnostics Inc (AXDX) - Total Liabilities
Based on the latest financial reports, Accelerate Diagnostics Inc (AXDX) has total liabilities worth $84.60 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Accelerate Diagnostics Inc (AXDX) defensive interval to measure how many days the company can operate on defensive assets alone.
Accelerate Diagnostics Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Accelerate Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data. Check AXDX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Accelerate Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Accelerate Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Microlise Group PLC
LSE:SAAS
|
UK | GBX59.69 Million |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
USA | $12.77 Million |
|
WINDFALL GEOTEK
F:L7C2
|
Germany | €309.27K |
|
New Energy Metals Corp
V:ENRG
|
Canada | CA$306.96K |
|
Ovoca Gold PLC
IR:OVXA
|
Ireland | €967.00K |
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
USA | $1.42 Million |
|
Colefax Group
LSE:CFX
|
UK | GBX42.80 Million |
|
Magnum Goldcorp Inc
V:MGI
|
Canada | CA$144.78K |
Liability Composition Analysis (1996–2024)
This chart breaks down Accelerate Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Accelerate Diagnostics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Accelerate Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Accelerate Diagnostics Inc (1996–2024)
The table below shows the annual total liabilities of Accelerate Diagnostics Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $84.60 Million | +65.05% |
| 2023-12-31 | $51.25 Million | -41.28% |
| 2022-12-31 | $87.28 Million | -26.11% |
| 2021-12-31 | $118.12 Million | -24.40% |
| 2020-12-31 | $156.24 Million | +10.18% |
| 2019-12-31 | $141.80 Million | +10.88% |
| 2018-12-31 | $127.89 Million | +1778.80% |
| 2017-12-31 | $6.81 Million | +35.17% |
| 2016-12-31 | $5.04 Million | -20.14% |
| 2015-12-31 | $6.31 Million | +65.51% |
| 2014-12-31 | $3.81 Million | +99.10% |
| 2013-12-31 | $1.91 Million | -19.54% |
| 2012-12-31 | $2.38 Million | +64.14% |
| 2011-12-31 | $1.45 Million | +6.60% |
| 2010-12-31 | $1.36 Million | +1.66% |
| 2009-12-31 | $1.34 Million | -5.48% |
| 2008-12-31 | $1.41 Million | +12.45% |
| 2007-12-31 | $1.26 Million | +13.43% |
| 2006-12-31 | $1.11 Million | -17.23% |
| 2005-12-31 | $1.34 Million | +35.59% |
| 2004-12-31 | $988.09K | -2.77% |
| 2003-12-31 | $1.02 Million | -20.56% |
| 2002-12-31 | $1.28 Million | +14.19% |
| 2001-12-31 | $1.12 Million | -39.23% |
| 2000-12-31 | $1.84 Million | +0.38% |
| 1999-12-31 | $1.84 Million | +13.45% |
| 1998-12-31 | $1.62 Million | +169.81% |
| 1997-12-31 | $600.00K | +50.00% |
| 1996-12-31 | $400.00K | -- |
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more